{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:36:35Z","timestamp":1792787795658,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":75,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Federico Foundation","id":[{"id":"https:\/\/ror.org\/022jgqd87","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"DOI":"10.1186\/s10020-026-01531-3","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:54:27Z","timestamp":1783166067000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PD-L1 and PD-L2 regulate in cell-autonomous and N-glycosylation-dependent manners the pro-tumorigenic characteristics and functions of human cancer-associated fibroblasts"],"prefix":"10.1186","volume":"32","author":[{"given":"Alaa","family":"Abu Raiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsipi","family":"Meshel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Kamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Lipin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raneen","family":"Tarabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Horvitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linor","family":"Rubinstein-Achiasaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Morein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jair","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adit","family":"Ben-Baruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"1531_CR1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J, Adler J, Dunger J, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630:493\u2013500.","journal-title":"Nature"},{"key":"1531_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584626","volume":"11","author":"F Antonangeli","year":"2020","unstructured":"Antonangeli F, Natalini A, Garassino MC, Sica A, Santoni A, Di Rosa F. Regulation of PD-L1 expression by NF-\u03baB in cancer. Front Immunol. 2020;11:584626.","journal-title":"Front Immunol"},{"key":"1531_CR3","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.3390\/cancers14143513","volume":"14","author":"T Baram","year":"2022","unstructured":"Baram T, Oren N, Erlichman N, Meshel T, Ben-Baruch A. Inflammation-driven regulation of PD-L1 and PD-L2, and their cross-interactions with protective soluble TNF\u03b1 receptors in human triple-negative breast cancer. Cancers (Basel). 2022;14:3513\u201340.","journal-title":"Cancers (Basel)"},{"key":"1531_CR4","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.3390\/cells9051222","volume":"9","author":"C Behm","year":"2020","unstructured":"Behm C, Blufstein A, Gahn J, et al. Cytokines Differently Define the Immunomodulation of Mesenchymal Stem Cells from the Periodontal Ligament. Cells. 2020;9:1222.","journal-title":"Cells"},{"key":"1531_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1021\/acs.jproteome.0c00521","volume":"20","author":"J Benicky","year":"2021","unstructured":"Benicky J, Sanda M, Brnakova Kennedy Z, et al. PD-L1 Glycosylation and Its Impact on Binding to Clinical Antibodies. J Proteome Res. 2021;20:485\u201397.","journal-title":"J Proteome Res"},{"key":"1531_CR6","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1016\/j.cell.2025.06.044","volume":"188","author":"D Boehmer","year":"2025","unstructured":"Boehmer D, Zanoni I. Interferons in health and disease. Cell. 2025;188:4480\u2013504.","journal-title":"Cell"},{"key":"1531_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102017","volume":"6","author":"Z Cao","year":"2025","unstructured":"Cao Z, Meng Z, Li J, et al. Interferon-gamma-stimulated antigen-presenting cancer-associated fibroblasts hinder neoadjuvant chemoimmunotherapy efficacy in lung cancer. Cell Rep Med. 2025;6:102017.","journal-title":"Cell Rep Med"},{"key":"1531_CR8","doi-asserted-by":"crossref","unstructured":"Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. Cancer Cell. 2018;33:463\u2013479 e410.","DOI":"10.1016\/j.ccell.2018.01.011"},{"key":"1531_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3892\/ol.2022.13596","volume":"25","author":"J Deng","year":"2023","unstructured":"Deng J, Jiang W, Liu L, Zhan W, Wu Y, Xu X. Research progress on the intrinsic non-immune function of PD-L1 in tumors (Review). Oncol Lett. 2023;25:10.","journal-title":"Oncol Lett"},{"key":"1531_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18:345\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"1531_CR11","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3390\/cancers14041042","volume":"14","author":"N Erlichman","year":"2022","unstructured":"Erlichman N, Baram T, Meshel T, Morein D, Da\u2019adoosh B, Ben-Baruch A. Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes. Cancers. 2022;14:1042\u201360.","journal-title":"Cancers"},{"key":"1531_CR12","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.3390\/cells12192338","volume":"12","author":"N Erlichman","year":"2023","unstructured":"Erlichman N, Meshel T, Baram T, et al. The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1. Cells. 2023;12:2338\u201360.","journal-title":"Cells"},{"key":"1531_CR13","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/ijc.31357","volume":"143","author":"Y Gao","year":"2018","unstructured":"Gao Y, Yang J, Cai Y, et al. IFN-gamma-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. Int J Cancer. 2018;143:931\u201343.","journal-title":"Int J Cancer"},{"key":"1531_CR14","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41556-020-0562-4","volume":"22","author":"Y Gao","year":"2020","unstructured":"Gao Y, Nihira NT, Bu X, et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020;22:1064\u201375.","journal-title":"Nat Cell Biol"},{"key":"1531_CR15","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19:1189\u2013201.","journal-title":"Cell Rep"},{"key":"1531_CR16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1471-2407-7-158","volume":"7","author":"I Garcia-Tunon","year":"2007","unstructured":"Garcia-Tunon I, Ricote M, Ruiz AA, Fraile B, Paniagua R, Royuela M. Influence of IFN-gamma and its receptors in human breast cancer. BMC Cancer. 2007;7:158.","journal-title":"BMC Cancer"},{"key":"1531_CR17","volume":"1","author":"EB Garon","year":"2020","unstructured":"Garon EB, Chih-Hsin Yang J, Dubinett SM. The Role of Interleukin 1beta in the Pathogenesis of Lung Cancer. JTO Clin Res Rep. 2020;1:100001.","journal-title":"JTO Clin Res Rep"},{"key":"1531_CR18","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1158\/0008-5472.CAN-25-1486","volume":"85","author":"Y Gu","year":"2025","unstructured":"Gu Y, Muller WJ. The multifaceted role of osteopontin in modulating the tumor microenvironment. Cancer Res. 2025;85:4049\u201361.","journal-title":"Cancer Res"},{"key":"1531_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53023-9","volume":"15","author":"Y Gu","year":"2024","unstructured":"Gu Y, Taifour T, Bui T, et al. Osteopontin is a therapeutic target that drives breast cancer recurrence. Nat Commun. 2024;15:9174.","journal-title":"Nat Commun"},{"key":"1531_CR20","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s10555-024-10186-7","volume":"43","author":"T Guo","year":"2024","unstructured":"Guo T, Xu J. Cancer-associated fibroblasts: a versatile mediator in tumor progression, metastasis, and targeted therapy. Cancer Metastasis Rev. 2024;43:1095\u2013116.","journal-title":"Cancer Metastasis Rev"},{"key":"1531_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107258","volume":"181","author":"G HeenatigalaPalliyage","year":"2023","unstructured":"HeenatigalaPalliyage G, Samart P, Bobbala S, et al. Chemotherapy-induced PDL-1 expression in cancer-associated fibroblasts promotes chemoresistance in NSCLC. Lung Cancer. 2023;181:107258.","journal-title":"Lung Cancer"},{"key":"1531_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02176-8","volume":"23","author":"M Jin","year":"2024","unstructured":"Jin M, Fang J, Peng J, et al. PD-1\/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies. Mol Cancer. 2024;23:266.","journal-title":"Mol Cancer"},{"key":"1531_CR23","doi-asserted-by":"publisher","first-page":"175883401774974","DOI":"10.1177\/1758834017749748","volume":"10","author":"N Karachaliou","year":"2018","unstructured":"Karachaliou N, Gonzalez-Cao M, Crespo G, et al. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Therapeutic Advances in Medical Oncology. 2018;10:1758834017749748.","journal-title":"Therapeutic Advances in Medical Oncology"},{"key":"1531_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-015-0080-7","volume":"6","author":"C Katanov","year":"2015","unstructured":"Katanov C, Lerrer S, Liubomirski Y, et al. Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-\u03b1 and the NF-\u03baB pathway. Stem Cell Res Ther. 2015;6:87.","journal-title":"Stem Cell Res Ther"},{"key":"1531_CR25","doi-asserted-by":"publisher","first-page":"1582532","DOI":"10.3389\/fimmu.2025.1582532","volume":"16","author":"X Lan","year":"2025","unstructured":"Lan X, Li W, Zhao K, Wang J, Li S, Zhao H. Revisiting the role of cancer-associated fibroblasts in tumor microenvironment. Front Immunol. 2025;16:1582532.","journal-title":"Front Immunol"},{"key":"1531_CR26","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s00262-020-02633-5","volume":"69","author":"H Lee","year":"2020","unstructured":"Lee H, Kim YA, Kim Y, et al. Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer. Cancer Immunology, Immunotherapy\u202f: CII. 2020;69:2381\u201391.","journal-title":"Cancer Immunology, Immunotherapy : CII"},{"key":"1531_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/antib10040044","volume":"10","author":"S Li","year":"2021","unstructured":"Li S, McCraw AJ, Gardner RA, Spencer DIR, Karagiannis SN, Wagner GK. Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors. Antibodies (Basel). 2021;10:44.","journal-title":"Antibodies (Basel)"},{"key":"1531_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-025-09105-7","volume":"68","author":"YY Lin","year":"2025","unstructured":"Lin YY, Ding JL, Shen HT, Lin YM, Adhidjaja EC, Chang SC. PD-1\/PD-L1 cancer immunotherapeutics reshape tumor microenvironment - clinical evidence and molecular mechanisms for AI-based precision medicine. Clin Rev Allergy Immunol. 2025;68:91.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1531_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.156046","volume":"272","author":"X Liu","year":"2025","unstructured":"Liu X. The paradoxical role of IFN-gamma in cancer: Balancing immune activation and immune evasion. Pathol Res Pract. 2025;272:156046.","journal-title":"Pathol Res Pract"},{"key":"1531_CR30","doi-asserted-by":"publisher","first-page":"12759","DOI":"10.21037\/apm-21-3471","volume":"10","author":"Y Liu","year":"2021","unstructured":"Liu Y, Gao Y, Lin T. Expression of interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-alpha) in non-small cell lung cancer and its relationship with the occurrence and prognosis of cancer pain. Ann Palliat Med. 2021;10:12759\u201366.","journal-title":"Ann Palliat Med"},{"key":"1531_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00757","volume":"10","author":"Y Liubomirski","year":"2019","unstructured":"Liubomirski Y, Lerrer S, Meshel T, et al. Tumor-stroma-inflammation networks promote pro-metastatic chemokines and aggressiveness characteristics in triple-negative breast cancer. Front Immunol. 2019;10:757.","journal-title":"Front Immunol"},{"key":"1531_CR32","doi-asserted-by":"publisher","first-page":"D370","DOI":"10.1093\/nar\/gkr703","volume":"40","author":"MA Lomize","year":"2012","unstructured":"Lomize MA, Pogozheva ID, Joo H, Mosberg HI, Lomize AL. OPM database and PPM web server: resources for positioning of proteins in membranes. Nucleic Acids Res. 2012;40:D370-376.","journal-title":"Nucleic Acids Res"},{"key":"1531_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/imm.13486","volume":"168","author":"AM Malkova","year":"2023","unstructured":"Malkova AM, Gubal AR, Petrova AL, et al. Pathogenetic role and clinical significance of interleukin-1beta in cancer. Immunology. 2023;168:203\u201316.","journal-title":"Immunology"},{"key":"1531_CR34","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-16-0224","volume":"22","author":"M Mandai","year":"2016","unstructured":"Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I. Dual faces of IFN\u03b3 in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin Cancer Res. 2016;22:2329\u201334.","journal-title":"Clin Cancer Res"},{"key":"1531_CR35","doi-asserted-by":"publisher","first-page":"6551","DOI":"10.1007\/s11033-021-06648-8","volume":"48","author":"A Mishra","year":"2021","unstructured":"Mishra A, Suman KH, Nair N, Majeed J, Tripathi V. An updated review on the role of the CXCL8-CXCR1\/2 axis in the progression and metastasis of breast cancer. Mol Biol Rep. 2021;48:6551\u201361.","journal-title":"Mol Biol Rep"},{"key":"1531_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1680838","volume":"16","author":"J Park","year":"2025","unstructured":"Park J, Skalhegg BS. Combination of PD-1\/PD-L1 and CTLA-4 inhibitors in the treatment of cancer - a brief update. Front Immunol. 2025;16:1680838.","journal-title":"Front Immunol"},{"key":"1531_CR37","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1074\/jbc.AC119.011747","volume":"295","author":"EA Philips","year":"2020","unstructured":"Philips EA, Garcia-Espana A, Tocheva AS, et al. The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals. J Biol Chem. 2020;295:4372\u201380.","journal-title":"J Biol Chem"},{"key":"1531_CR38","doi-asserted-by":"crossref","unstructured":"Qodir N, Pramudhito D, Legiran, et al.: Tumor Necrosis Factor-Alpha and Its Association With Breast Cancer: A Systematic Review. World J Oncol. 2025;16:143\u2013151.","DOI":"10.14740\/wjon2532"},{"key":"1531_CR39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41419-019-1497-1","volume":"10","author":"T Ren","year":"2019","unstructured":"Ren T, Zheng B, Huang Y, et al. Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways. Cell Death Dis. 2019;10:261.","journal-title":"Cell Death Dis"},{"key":"1531_CR40","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3390\/cancers13061472","volume":"13","author":"L Rubinstein-Achiasaf","year":"2021","unstructured":"Rubinstein-Achiasaf L, Morein D, Ben-Yaakov H, et al. Persistent inflammatory stimulation drives the conversion of MSCs to inflammatory CAFs that promote pro-metastatic characteristics in breast cancer cells. Cancers. 2021;13:1472\u201399.","journal-title":"Cancers"},{"key":"1531_CR41","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.3390\/cancers15174299","volume":"15","author":"G Shi","year":"2023","unstructured":"Shi G, Hu Y. TNFR1 and TNFR2, Which Link NF-kappaB Activation, Drive Lung Cancer Progression, Cell Dedifferentiation, and Metastasis. Cancers. 2023;15:4299.","journal-title":"Cancers"},{"key":"1531_CR42","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1471-2407-11-130","volume":"11","author":"G Soria","year":"2011","unstructured":"Soria G, Ofri-Shahak M, Haas I, et al. Inflammatory mediators in breast cancer: coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer. 2011;11:130.","journal-title":"BMC Cancer"},{"key":"1531_CR43","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lungcan.2019.09.013","volume":"137","author":"K Teramoto","year":"2019","unstructured":"Teramoto K, Igarashi T, Kataoka Y, et al. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer. Lung Cancer. 2019;137:56\u201363.","journal-title":"Lung Cancer"},{"key":"1531_CR44","doi-asserted-by":"publisher","first-page":"R421","DOI":"10.1530\/ERC-17-0309","volume":"25","author":"C Tulotta","year":"2018","unstructured":"Tulotta C, Ottewell P. The role of IL-1B in breast cancer bone metastasis. Endocr Relat Cancer. 2018;25:R421\u201334.","journal-title":"Endocr Relat Cancer"},{"key":"1531_CR45","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1327494","volume":"6","author":"H Wang","year":"2017","unstructured":"Wang H, Yao H, Li C, et al. PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation. Oncoimmunology. 2017;6:e1327494.","journal-title":"Oncoimmunology"},{"key":"1531_CR46","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41416-022-02084-y","volume":"128","author":"Y Wang","year":"2023","unstructured":"Wang Y, Du J, Gao Z, et al. Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. Br J Cancer. 2023;128:1196\u2013207.","journal-title":"Br J Cancer"},{"key":"1531_CR47","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.3390\/cancers14215270","volume":"14","author":"X Wang","year":"2022","unstructured":"Wang X, Yang C, Korner H, Ge C. Tumor Necrosis Factor: What Is in a Name? Cancers. 2022;14:5270. PMID 36358688.","journal-title":"Cancers"},{"key":"1531_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1601756","volume":"16","author":"H Xavier","year":"2025","unstructured":"Xavier H, Gireesh AGM, Thomas JA, et al. Chemokines: humble yet mighty players in the tumour microenvironment. Front Immunol. 2025;16:1601756.","journal-title":"Front Immunol"},{"key":"1531_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12943-025-02243-8","volume":"24","author":"Y Xie","year":"2025","unstructured":"Xie Y, Liu F, Wu Y, et al. Inflammation in cancer: therapeutic opportunities from new insights. Mol Cancer. 2025;24:51.","journal-title":"Mol Cancer"},{"key":"1531_CR50","doi-asserted-by":"publisher","first-page":"e002699","DOI":"10.1136\/jitc-2021-002699","volume":"9","author":"Y Xu","year":"2021","unstructured":"Xu Y, Gao Z, Hu R, et al. PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy. J Immunother Cancer. 2021;9:e002699.","journal-title":"J Immunother Cancer"},{"key":"1531_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1359532","volume":"15","author":"Y Yang","year":"2024","unstructured":"Yang Y, Yan X, Bai X, Yang J, Song J. Programmed cell death-ligand 2: new insights in cancer. Front Immunol. 2024;15:1359532.","journal-title":"Front Immunol"},{"key":"1531_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105741","volume":"170","author":"H Ying","year":"2021","unstructured":"Ying H, Zhang X, Duan Y, et al. Non-cytomembrane PD-L1: an atypical target for cancer. Pharmacol Res. 2021;170:105741.","journal-title":"Pharmacol Res"},{"key":"1531_CR53","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12885-021-07970-x","volume":"21","author":"K Yoshikawa","year":"2021","unstructured":"Yoshikawa K, Ishida M, Yanai H, Tsuta K, Sekimoto M, Sugie T. Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer. BMC Cancer. 2021;21:239.","journal-title":"BMC Cancer"},{"key":"1531_CR54","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41423-023-01013-0","volume":"20","author":"T Yoshimura","year":"2023","unstructured":"Yoshimura T, Li C, Wang Y, Matsukawa A. The chemokine monocyte chemoattractant protein-1\/CCL2 is a promoter of breast cancer metastasis. Cell Mol Immunol. 2023;20:714\u201338.","journal-title":"Cell Mol Immunol"},{"key":"1531_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104222","volume":"193","author":"J Zhou","year":"2024","unstructured":"Zhou J, Du Z, Liang Y, Zhang S. Benefits and risks of PD-1\/PD-L1 inhibitors for recurrent small cell lung cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2024;193:104222.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-026-01531-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01531-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01531-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:53:16Z","timestamp":1789645996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10020-026-01531-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1531"],"URL":"https:\/\/doi.org\/10.1186\/s10020-026-01531-3","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Information is provided in \"\n                      \n                      \", under the section \"\n                      \n                      \".","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"150"}}